RecruitingNCT07101094
Treatment experiences with KarXT in schizophrenia
About this title
Read the official source — NCT07101094Observational studyAges 18+United States
Understand this study
Who could participate?
Listed age limits: from 18 years.
What will I do during this study?
This is a treatment-satisfaction and preference study of adults who are already prescribed xanomeline and trospium chloride. The study does not assign the medication; the registry entry does not specify how satisfaction or preferences are collected.
- Listed locations
- Orange and 19 more locationsSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 22, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 300
- Sponsor
- Bristol-Myers Squibb
- Sponsor type
- Pharmaceutical company
- Study type
- Observational
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT07101094
- Official title
Show the full official title
Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Orange · San Jose · Miami
17 more locations
- Evanston
- Baltimore
- Bel Air
- Catonsville
- Belmont
- Boston
- South Dartmouth
- Grand Island
- Omaha
- Belle Mead
- New York
- Kinston
- Rose Hill
- Westlake
- Fort Mill
- El Paso
- Longview
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Bristol-Myers Squibb, a pharmaceutical company.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as recruiting.
